Hu antigen R and tristetraprolin: Counter‐regulators of rat apical sodium‐dependent bile acid transporter by way of effects on messenger RNA stability
Frank Chen, Ann‐Bin Shyu, Benjamin L. Shneider – 17 June 2011
Treatment of recurrent hepatocellular carcinoma after liver transplantation
Eric Davis, Russell Wiesner, Juan Valdecasas, Yoshiaki Kita, Massimo Rossi, Myron Schwartz – 17 June 2011
Aldo‐keto reductase‐7A protects liver cells and tissues from acetaminophen‐induced oxidative stress and hepatotoxicity
Munzir M.E. Ahmed, Tao Wang, Yu Luo, Shuilong Ye, Qiao Wu, Zongsheng Guo, Bill D. Roebuck, Thomas R. Sutter, James Y. Yang – 17 June 2011 – Aldo‐keto reductase‐7A (AKR7A) is an enzyme important for bioactivation and biodetoxification. Previous studies suggested that Akr7a might be transcriptionally regulated by oxidative stress‐responsive transcription factor nuclear factor erythroid 2 p45‐related factor 2 (Nrf2), a protein highly responsive to acetaminophen (APAP) or its intermediate metabolite, N‐acetyl‐p‐benzoquinoneimine (NAPQI).
Publications in HEPATOLOGY: Is there a pro–United States bias?
Patrick S. Kamath – 17 June 2011
Liver transplant recipient survival benefit with living donation in the model for endstage liver disease allocation era
Carl L. Berg, Robert M. Merion, Tempie H. Shearon, Kim M. Olthoff, Robert S. Brown, Talia B. Baker, Gregory T. Everson, Johnny C. Hong, Norah Terrault, Paul H. Hayashi, Robert A. Fisher, James E. Everhart – 17 June 2011 – Receipt of a living donor liver transplant (LDLT) has been associated with improved survival compared with waiting for a deceased donor liver transplant (DDLT).
The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: An international collaborative study
Neeraj Bhala, Paul Angulo, David van der Poorten, Eric Lee, Jason M. Hui, Giorgio Saracco, Leon A. Adams, Phunchai Charatcharoenwitthaya, Joanne H. Topping, Elisabetta Bugianesi, Christopher P. Day, Jacob George – 17 June 2011 – Information on the long‐term prognosis of nonalcoholic fatty liver disease (NAFLD) is limited. We sought to describe the long‐term morbidity and mortality of patients with NAFLD with advanced fibrosis or cirrhosis by prospectively studying 247 such patients from four international centers (in Australia, USA, UK and Italy).
Genome‐wide copy number analyses identified novel cancer genes in hepatocellular carcinoma
Deshui Jia, Lin Wei, Weijie Guo, Ruopeng Zha, Meiyan Bao, Zhiao Chen, Yingjun Zhao, Chao Ge, Fangyu Zhao, Taoyang Chen, Ming Yao, Jinjun Li, Hongyang Wang, Jianren Gu, Xianghuo He – 17 June 2011 – A powerful way to identify driver genes with causal roles in carcinogenesis is to detect genomic regions that undergo frequent alterations in cancers. Here we identified 1,241 regions of somatic copy number alterations in 58 paired hepatocellular carcinoma (HCC) tumors and adjacent nontumor tissues using genome‐wide single nucleotide polymorphism (SNP) 6.0 arrays.
Can positron emission tomography with the dual tracers [11C]acetate and [18F]fludeoxyglucose predict microvascular invasion in hepatocellular carcinoma?
Tan To Cheung, See Ching Chan, Chi Lai Ho, Kenneth Siu Ho Chok, Albert Chi Yan Chan, William Wei Sharr, Kelvin Kwok Chai Ng, Ronnie Tung Ping Poon, Chung Mau Lo, Sheung Tat Fan – 17 June 2011 – Microvascular invasion is a poor prognostic indicator of the recurrence of hepatocellular carcinoma (HCC) after surgical treatment. Positron emission tomography (PET) with [18F]fludeoxyglucose ([18F]FDG) as a tracer has been employed to predict the prognosis before surgery for various kinds of tumors, but it has not been found to be sensitive enough for HCC.
Both innate and adaptive immunity mediate protective immunity against hepatitis C virus infection in chimpanzees
Heidi Barth, Jolanta Rybczynska, Romuald Patient, Youkyung Choi, Ronda K. Sapp, Thomas F. Baumert, Kris Krawczynski, T. Jake Liang – 14 June 2011 – Understanding the immunological correlates associated with protective immunity following hepatitis C virus (HCV) reexposure is a prerequisite for the design of effective HCV vaccines and immunotherapeutics. In this study we performed a comprehensive analysis of innate and adaptive immunity following HCV reexposure of two chimpanzees that had previously recovered from HCV‐JFH1 infection.
Response‐guided peg‐interferon plus ribavirin treatment duration in chronic hepatitis C: Meta‐analyses of randomized, controlled trials and implications for the future
Vincent Di Martino, Carine Richou, Jean‐Paul Cervoni, Jose M. Sanchez‐Tapias, Donald M. Jensen, Alessandra Mangia, Maria Buti, Frances Sheppard, Peter Ferenci, Thierry Thévenot – 14 June 2011 – Response‐guided pegylated interferon (peg‐IFN) plus ribavirin (P/R) therapy trials on genotype (G)1 and G2/G3 hepatitis C virus–infected patients provide contradictory results. We conducted meta‐analyses of randomized, controlled trials to address (1) the benefit of a 72‐week extended‐duration therapy in G1‐slow responders and (2) adequate shortened duration therapy in G1 and G2/G3‐rapid responders.